Receptos Announces Proposed Underwritten Public Offering of Common Stock
June 17, 2014 16:08 ET
|
Receptos, Inc.
SAN DIEGO, June 17, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, announced...
Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis
June 09, 2014 16:05 ET
|
Receptos, Inc.
– Study met primary efficacy endpoint with statistical significance after 24 weeks of treatment –
– Safety data are supportive of differentiated product profile...
Receptos Reports First Quarter 2014 Financial Results
May 12, 2014 08:00 ET
|
Receptos, Inc.
- Top-line results of Phase 2 trial of RPC1063 in relapsing multiple sclerosis expected in mid-2014 -
- Phase 3 trial of RPC1063 in relapsing multiple sclerosis enrolling patients globally -...
Receptos to Hold First Quarter 2014 Financial Results Conference Call and Webcast
May 07, 2014 08:00 ET
|
Receptos, Inc.
SAN DIEGO, May 7, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, will announce...
Receptos to Present at Bank of America Merrill Lynch 2014 Health Care Conference
May 06, 2014 08:00 ET
|
Receptos, Inc.
SAN DIEGO, May 6, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
Receptos to Present at Deutsche Bank Securities Annual Healthcare Conference
May 01, 2014 08:00 ET
|
Receptos, Inc.
SAN DIEGO, May 1, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
Receptos to Deliver Scientific Presentations Regarding RPC1063 at the 2014 American Academy of Neurology (AAN) Annual Meeting
April 28, 2014 05:00 ET
|
Receptos, Inc.
SAN DIEGO, April 28, 2014 (GLOBE NEWSWIRE) -- Receptos Inc. (Nasdaq:RCPT) today announced that Company personnel will deliver two scientific poster presentations regarding its lead program, RPC1063,...
Receptos Announces Appointment of Mary Lynne Hedley, Ph.D. as Director
April 14, 2014 16:56 ET
|
Receptos, Inc.
SAN DIEGO, April 14, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
Receptos to Present at BioCentury Future Leaders Conference
March 20, 2014 08:00 ET
|
Receptos, Inc.
SAN DIEGO, March 20, 2014 (GLOBE NEWSWIRE) -- Receptos, Inc. (Nasdaq:RCPT), a biopharmaceutical company developing therapeutic candidates for the treatment of immune and metabolic diseases, today...
Receptos Reports Fourth Quarter and Year End 2013 Operational and Financial Results
March 05, 2014 16:05 ET
|
Receptos, Inc.
- Favorable interim results from Phase 2 trial of RPC1063 in relapsing multiple sclerosis consistent with differentiated profile; top-line data expected mid-2014 -
- Phase 3 trial of RPC1063 in...